% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Jan 20, 2011 8:49 AM Flag

    TEVA watch:

    Rexahn Pharmaceuticals: Teva Pharmaceutical (TEVA) increases its investment in Rexahn for continued research and development of pre-clinical anti-cancer compound, RX-3117 (1.22)
    Co announces that Teva Pharmaceutical (TEVA) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share. This investment by Teva was made pursuant to the terms of the Securities Purchase Agreement, dated June 26, 2009, as amended. The investment money will be used for the purpose of supporting the research and development program for the pre-clinical stage, anti-cancer compound RX-3117. After this transaction, Teva will own 6.29% of the outstanding shares of Rexahn.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.405+0.030(+8.00%)Oct 21 4:00 PMEDT